Annual Report 2021

Department of Musculoskeletal Oncology

Department of Musculoskeletal Oncology

Introduction

 The Department of Musculoskeletal Oncology of NCCHE is a team consisting of two orthopedic surgeons that started in 2021. We strive to provide expert interdisciplinary care for the benign and malignant bone and soft tissue tumors and tumor-like conditions. Currently, we conduct a variety of bone and soft tissue tumor surgeries with the aid of other department staff including plastic surgery, thoracic surgery and colorectal surgery. Chemotherapy and radiotherapy for malignant musculoskeletal tumors are currently conducted in the Departments of Medical Oncology and Radiotherapy respectively.

The Team and What We Do

 Our outpatient service is generally open three days a week (Mondays. Thursdays, Fridays) for patients with a variety of musculoskeletal tumors. We also manage patients who suffer from bone metastases and other orthopedic diseases, and consult with other cancer specialists on a daily basis. To provide prosthetic and orthotic care for our patients, a special outpatient service is open on Fridays. A constant number of over four patients are hospitalized for operations or radiation therapy. One or two major operations are routinely performed every week. In 2021, as shown in Table 1, 39 operations were performed. A total of nine reconstructive operations were conducted in collaboration with plastic surgeons to achieve adequate soft tissue coverage after the resection of malignant tumors of the trunk or limb-salvage operations for sarcomas of the extremities. With regard to the patients’ postoperative course, we have been collaborating with a physical therapist to rehabilitate the musculoskeletal system in cancer-bearing patients.

Research activities

 We have been attending multi-institutional study groups including The Japan Clinical Oncology Group (JCOG) and The Japan Musculoskeletal Oncology Group (JMOG) to produce novel evidence for rare musculoskeletal tumors. We are also engaged in developing a system for early detection of bone metastasis and spinal canal invasion by metastatic tumors using a subtraction method with CT-based images in collaboration with radiologists.

Clinical trials

1. A multi-institutional randomized phase II clinical trial of second line chemotherapy for advanced soft tissue sarcoma (JCOG 1802) since 2019

Table 1.Type of surgical procedure (2021)

Education

 We have been engaging in several educational lectures for the medical staff to promote the specific care regarding musculoskeletal oncology. We also provide some instructive lectures for the medical staff in the community.

Future Prospects

 Our division continues to focus on the development of novel therapeutic tools for patients with bone and soft tissue tumors in collaboration with other clinical divisions and research institutes.

List of papers published in 2021

Journal

1. Tsuchiya R, Yoshimatsu Y, Noguchi R, Sin Y, Ono T, Akiyama T, Sugaya J, Nakatani F, Kojima N, Yoshida A, Ohtori S, Kawai A, Kondo T. Establishment and characterization of NCC-UPS3-C1: a novel patient-derived cell line of undifferentiated pleomorphic sarcoma. Human cell, 35:384-391, 2022

2. Toki S, Sone M, Yoshida A, Nishisho T, Gokita T, Kobayashi E, Nakatani F, Chuman H, Sugawara S, Arai Y, Kawai A. Image-guided core needle biopsy for musculoskeletal lesions. Journal of orthopaedic science: official journal of the Japanese Orthopaedic Association, 27:448-455, 2022

3. Sin Y, Yoshimatsu Y, Noguchi R, Tsuchiya R, Ono T, Akiyama T, Nakatani F, Sugaya J, Yoshida A, Kawai A, Kondo T. Establishment and characterization of NCC-MPNST6-C1: a novel patient-derived cell line of malignant peripheral nerve sheath tumors. Human cell, 35:400-407, 2022

4. Sin Y, Yoshimatsu Y, Noguchi R, Tsuchiya R, Ono T, Akiyama T, Iwata S, Sugaya J, Yoshida A, Kawai A, Kondo T. Establishment and characterization of NCC-DDLPS5-C1: a novel patient-derived cell line of dedifferentiated liposarcoma. Human cell, 35:936-943, 2022

5. Ono T, Yoshimatsu Y, Noguchi R, Sin Y, Tsuchiya R, Akiyama T, Sugaya J, Fukushima S, Kojima N, Yoshida A, Kawai A, Kondo T. Establishment and characterization of NCC-UPS4-C1: a novel cell line of undifferentiated pleomorphic sarcoma from a patient with Li-Fraumeni syndrome. Human cell, 35:756-766, 2022

6. Tsuchiya R, Yoshimatsu Y, Noguchi R, Sin Y, Ono T, Akiyama T, Sugaya J, Kobayashi E, Kojima N, Yoshida A, Ohtori S, Kawai A, Kondo T. Establishment and Characterization of NCC-MFS5-C1: A Novel Patient-Derived Cell Line of Myxofibrosarcoma. Cells, 11:2022

7. Yoshimatsu Y, Noguchi R, Tsuchiya R, Sin Y, Ono T, Sugaya J, Iwata S, Yoshida A, Kawai A, Kondo T. Establishment and characterization of NCC-MFS4-C1: a novel patient-derived cell line of myxofibrosarcoma. Human cell, 34:1911-1918, 2021

8. Tsuchiya R, Yoshimatsu Y, Noguchi R, Sin Y, Ono T, Sei A, Takeshita F, Sugaya J, Nakatani F, Yoshida A, Ohtori S, Kawai A, Kondo T. Establishment and characterization of NCC-ssRMS2-C1: a novel patient-derived cell line of spindle cell/sclerosing rhabdomyosarcoma. Human cell, 34:1569-1578, 2021

9. Kawai A, Naka N, Shimomura A, Takahashi S, Kitano S, Imura Y, Yonemori K, Nakatani F, Iwata S, Kobayashi E, Outani H, Tamiya H, Naito Y, Yamamoto N, Doi T. Efficacy and safety of TAS-115, a novel oral multi-kinase inhibitor, in osteosarcoma: an expansion cohort of a phase I study. Investigational new drugs, 39:1559-1567, 2021

10. Tsuchiya R, Yoshimatsu Y, Noguchi R, Sin Y, Ono T, Sei A, Takeshita F, Sugaya J, Iwata S, Yoshida A, Ohtori S, Kawai A, Kondo T. Establishment and characterization of NCC-MFS3-C1: a novel patient-derived cell line of myxofibrosarcoma. Human cell, 34:1266-1273, 2021

11. Nakagawa M, Sekimizu M, Endo M, Kobayashi E, Iwata S, Fukushima S, Yoshida A, Kitabayashi I, Ichikawa H, Kawai A, Nakatani F. Prognostic impact of IDH mutations in chondrosarcoma. Journal of orthopaedic science: official journal of the Japanese Orthopaedic Association, 2021

12. Yoshimatsu Y, Noguchi R, Sin Y, Tsuchiya R, Ono T, Sei A, Sugaya J, Iwata S, Yoshida A, Kawai A, Kondo T. Establishment and characterization of NCC-LGFMS1-C1: a novel patient-derived cell line of low-grade fibromyxoid sarcoma. Human cell, 34:1919-1928, 2021

13. Yoshimatsu Y, Noguchi R, Tsuchiya R, Ono T, Sin Y, Akane S, Sugaya J, Mori T, Fukushima S, Yoshida A, Kawai A, Kondo T. Establishment and characterization of novel patient-derived cell lines from giant cell tumor of bone. Human cell, 34:1899-1910, 2021

14. Tsuchiya R, Yoshimatsu Y, Noguchi R, Ono T, Sei A, Takeshita F, Sugaya J, Fukushima S, Yoshida A, Ohtori S, Kawai A, Kondo T. Establishment and characterization of NCC-DDLPS3-C1: a novel patient-derived cell line of dedifferentiated liposarcoma. Human cell, 34:1008-1018, 2021

15. Tsuchiya R, Yoshimatsu Y, Noguchi R, Ono T, Sei A, Takeshita F, Sugaya J, Iwata S, Yoshida A, Ohtori S, Kawai A, Kondo T. Establishment and characterization of NCC-SS4-C1: a novel patient-derived cell line of synovial sarcoma. Human cell, 34:998-1007, 2021

16. Kim Y, Kobayashi E, Suehara Y, Ito A, Kubota D, Tanzawa Y, Endo M, Nakatani F, Nakatsura T, Kawai A, Kaneko K, Kitano S. Immunological status of peripheral blood is associated with prognosis in patients with bone and soft-tissue sarcoma. Oncology letters, 21:212, 2021

17. Nakamura T, Sugaya J, Naka N, Kobayashi H, Okuma T, Kunisada T, Asanuma K, Outani H, Nishimura S, Kawashima H, Akiyama T, Yasuda T, Miwa S, Sudo A, Ueda T. Standard Treatment Remains the Recommended Approach for Patients with Bone Sarcoma Who Underwent Unplanned Surgery: Report from the Japanese Musculoskeletal Oncology Group. Cancer management and research, 12:10017-10022, 2020